Plain-English translation of NCT06402851 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing three different strategies for preventing blood clots in people who have both an irregular heartbeat (atrial fibrillation) and severe kidney disease. You would be randomly assigned to take either warfarin (a traditional blood thinner), edoxaban (a newer blood thinner), or no blood thinner at all. The researchers want to understand which approach works best and is safest for your situation.
People with severe kidney disease and irregular heartbeats face a difficult choice: they need blood thinners to prevent strokes, but these medications can be risky when kidneys don't work well. This medication hasn't been well studied in this specific group, so doctors aren't sure what the best treatment approach should be.
You likely qualify if…
You likely don't qualify if…
If you join this study, you would be randomly assigned to one of three groups: taking warfarin, taking edoxaban, or taking no blood thinner medication. You would attend regular clinic visits so researchers can monitor your health, check your blood work, and watch for any bleeding or clotting problems. The study involves about 1,500 patients and will track your outcomes over time to see which approach is safest and most effective for people with your condition.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
Brazil